Jump to content

Vortioxetine

From Pharmacopedia
Revision as of 18:42, 15 May 2026 by MDElliottMD (talk | contribs) (Comprehensive categorization: +Multimodal Serotonergic Agents)
Antidepressant
Vortioxetine
Trintellix

Experience

👥 No personal reports yet
No clinical reports yet

Log in to add your own experience.

Problems

No problems yet. Be the first to suggest one.

+ Add a problem

Titration strategies

No titration strategies yet. Be the first to suggest one.

+ Add a titration strategy

Effects

No effects listed yet. Be the first to suggest one.

+ Add an effect

Interactions

Pharmacogenomic + mechanism interactions4 edges
Pharmacogenomic guideline recommendationsCPIC and Dutch Pharmacogenetics Working Group clinical guidelines
Phenotype:CYP2D6 normal metabolizer monitor CPIC A 70 / 100
CPIC rec 8095308 [Strong]: Initiate therapy with recommended starting dose. CPIC pair-level A (CYP2D6, CYP2C19, CYP2B6, SLC6A4, HTR2A and Serotonin Reuptake Inhibitor Antidepressants) [PMID 37032427]
Phenotype:CYP2D6 poor metabolizer prefer alternative CPIC A 55 / 100
CPIC rec 8095315 [Moderate]: Initiate 50% of starting dose (e.g., 5 mg) and titrate to the maximum recommended dose of 10 mg or consider a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2D6. CPIC pair-level A (CYP2D6, CYP2C19, CYP2B6, SLC6A4, HTR2A and Serotonin Reuptake Inhibitor Antidepressants) [PMID 37032427] FDA labeling (Dosage and Administration, Clinical Pharmacology)
Phenotype:CYP2D6 intermediate metabolizer monitor CPIC A 45 / 100
CPIC rec 8095312 [Moderate]: Initiate therapy with recommended starting dose. CPIC pair-level A (CYP2D6, CYP2C19, CYP2B6, SLC6A4, HTR2A and Serotonin Reuptake Inhibitor Antidepressants) [PMID 37032427]
Phenotype:CYP2D6 ultrarapid metabolizer prefer alternative CPIC A 30 / 100
CPIC rec 8095295 [Optional]: Select alternative drug not predominantly metabolized by CYP2D6. If vortioxetine use is warranted, initiate therapy at standard starting dose and titrate to maintenance dose based on efficacy and side effects. Increasing the target maintenance dose by 50% or more may be needed for efficacy. CPIC pair-level A (CYP2D6, CYP2C19, CYP2B6, SLC6A4, HTR2A and Serotonin Reuptake Inhibitor Antidepressants) [PMID 37032427] FDA labeling (Dosage and Administration, Clinical Pharmacology)

Patient experience

Fluoxetine via Category:Antidepressants👤 exp n/a/5 outcome n/a (n=1)⚕️ exp 1.0/5 outcome +33.0 (n=1)

Relevant anecdote

No anecdotes yet. Share a relevant one.

+ Add an anecdote

Relevant Literature

No literature entries yet.

Log in to submit relevant literature.

Summary
Classes
Antidepressant
Common uses
Pharmacy
Pharmacology
Purported mechanism
Multimodal serotonergic agent